{"id":"https://openalex.org/W160400900","doi":null,"title":"Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.","display_name":"Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.","publication_year":2010,"publication_date":"2010-07-01","ids":{"openalex":"https://openalex.org/W160400900","mag":"160400900","pmid":"https://pubmed.ncbi.nlm.nih.gov/20864916"},"language":"en","primary_location":{"id":"pmid:20864916","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20864916","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical advances in hematology & oncology : H&O","raw_type":"Clinical Trial, Phase II"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018054038","display_name":"David Robert Spigel","orcid":"https://orcid.org/0000-0003-3215-9465","observed_orcids":["https://orcid.org/0000-0003-3215-9465"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David R Spigel","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, TN 37203, USA, dspigel@tnonc.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, TN 37203, USA, dspigel@tnonc.com","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057644746","display_name":"Filippo Greco","orcid":"https://orcid.org/0000-0002-0265-5073","observed_orcids":["https://orcid.org/0000-0002-0265-5073"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F Anthony Greco","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053359739","display_name":"David Michael Waterhouse","orcid":"https://orcid.org/0000-0001-5589-9939","observed_orcids":["https://orcid.org/0000-0001-5589-9939"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Waterhouse","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110047769","display_name":"Dianna L. Shipley","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dianna Shipley","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050610940","display_name":"Cassie Michelle Lane","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cassie M Lane","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108425845","display_name":"Elizabeth R. V\u00e1zquez","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elizabeth R Vazquez","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113913364","display_name":"Bobby L. Clark","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bobby L Clark","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103514741","display_name":"Jeffrey R. Infante","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeffrey R Infante","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028472820","display_name":"Johanna C. Bendell","orcid":"https://orcid.org/0000-0001-9426-5891","observed_orcids":["https://orcid.org/0000-0001-9426-5891"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Johanna C Bendell","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072308451","display_name":"Howard A. Burris","orcid":"https://orcid.org/0000-0002-1501-2931","observed_orcids":["https://orcid.org/0000-0002-1501-2931"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Howard A Burris","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5065917441","display_name":"John Daniel Hainsworth","orcid":"https://orcid.org/0000-0002-2848-6546","observed_orcids":["https://orcid.org/0000-0002-2848-6546"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John D Hainsworth","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.6495,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.69815641,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"8","issue":"7","first_page":"480","last_page":"5, 498"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10335","display_name":"Colorectal Cancer Surgical Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12064","display_name":"Intraperitoneal and Appendiceal Malignancies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.9950000047683716},{"id":"https://openalex.org/keywords/folfox6","display_name":"FOLFOX6","score":0.9300000071525574},{"id":"https://openalex.org/keywords/oxaliplatin","display_name":"oxaliplatin","score":0.9139999747276306},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9129999876022339},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":1.0},{"id":"https://openalex.org/keywords/first-line-chemotherapy","display_name":"first-line chemotherapy","score":0.7080000042915344},{"id":"https://openalex.org/keywords/anti-egfr-therapy","display_name":"anti-EGFR therapy","score":0.7350000143051147},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.6660000085830688},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9940000176429749},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.843999981880188},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.6480000019073486},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.39800000190734863},{"id":"https://openalex.org/keywords/early-trial-termination","display_name":"early trial termination","score":0.7379999756813049},{"id":"https://openalex.org/keywords/deep-vein-thrombosis","display_name":"deep vein thrombosis","score":0.6840000152587891},{"id":"https://openalex.org/keywords/sensory-neuropathy","display_name":"sensory neuropathy","score":0.531000018119812}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9562455415725708},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8700875639915466},{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.8449020385742188},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.694259524345398},{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.6527255773544312},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.5791317224502563},{"id":"https://openalex.org/C2778260052","wikidata":"https://www.wikidata.org/wiki/Q117636","display_name":"FOLFOX","level":5,"score":0.5517923831939697},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.49341264367103577},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.4711398482322693},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.46737757325172424},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.44185927510261536},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.44067704677581787},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4187561273574829},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.36873549222946167},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3669809103012085},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.26308637857437134},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.23539528250694275}],"mesh":[{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000068818","descriptor_name":"Cetuximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002955","descriptor_name":"Leucovorin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D002955","descriptor_name":"Leucovorin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D008207","descriptor_name":"Lymphatic Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009944","descriptor_name":"Organoplatinum Compounds","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D009944","descriptor_name":"Organoplatinum Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":1,"locations":[{"id":"pmid:20864916","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20864916","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical advances in hematology & oncology : H&O","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9922999739646912}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":18,"referenced_works":["https://openalex.org/W1782669727","https://openalex.org/W1979300931","https://openalex.org/W2002226820","https://openalex.org/W2097121246","https://openalex.org/W2097644228","https://openalex.org/W2107666024","https://openalex.org/W2125447919","https://openalex.org/W2128176473","https://openalex.org/W2139119404","https://openalex.org/W2139248078","https://openalex.org/W2140035322","https://openalex.org/W2141632745","https://openalex.org/W2142374454","https://openalex.org/W2142564546","https://openalex.org/W2155311724","https://openalex.org/W2155977433","https://openalex.org/W2157769714","https://openalex.org/W2170655985"],"related_works":["https://openalex.org/W2597492983","https://openalex.org/W2082108965","https://openalex.org/W2255147260","https://openalex.org/W2598390777","https://openalex.org/W1972813927","https://openalex.org/W2589765552","https://openalex.org/W2079096399","https://openalex.org/W1504745397","https://openalex.org/W4244653091","https://openalex.org/W2090325319"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1],"examine":[2],"FOLFOX/bevacizumab/cetuximab":[3],"in":[4,276,281,292],"the":[5,33,253],"first-line":[6,282],"treatment":[7,284],"of":[8],"metastatic":[9],"colorectal":[10],"cancer":[11],"(mCRC).":[12],"DESIGN:":[13],"Randomized":[14],"phase":[15],"II":[16],"trial":[17,34,124],"aimed":[18],"at":[19],"achieving":[20],"a":[21,38,119],"60%":[22],"objective":[23],"response":[24,254],"rate":[25],"(ORR).":[26],"Due":[27],"to":[28,37,249],"frequent":[29],"cetuximab-related":[30],"hypersensitivity":[31],"reactions":[32],"was":[35,129,138,158,183,193,264],"amended":[36],"single-arm":[39],"design.":[40],"Eligibility:":[41],"Previously":[42],"untreated":[43],"mCRC,":[44],"measurable":[45],"disease,":[46],"Eastern":[47],"Cooperative":[48],"Oncology":[49],"Group":[50],"performance":[51],"status":[52],"(ECOG-PS)":[53],"0-1.":[54],"TREATMENT:":[55],"Modified":[56],"FOLFOX6":[57],"(oxaliplatin":[58],"85":[59],"mg/m\u00b2,":[60],"leucovorin":[61],"350":[62],"mg,":[63],"and":[64,94,235,257],"5-fluorouracil":[65],"400":[66,83],"mg/m\u00b2":[67,84,90],"bolus;":[68],"2.4":[69],"g/m\u00b2":[70],"infusion,":[71],"46":[72],"h)":[73],"day":[74,80,86],"1;":[75,81],"bevacizumab":[76],"5":[77],"mg/kg":[78],"on":[79,85,91],"cetuximab":[82,247],"1,":[87],"then":[88],"250":[89],"days":[92,98],"1":[93,171],"8,":[95],"every":[96,107],"14":[97],"(1":[99],"cycle)":[100],"until":[101],"progressive":[102],"disease":[103],"(PD);":[104],"restaging":[105],"occurred":[106],"4":[108],"cycles.":[109],"RESULTS:":[110],"With":[111],"emerging":[112],"negative":[113],"progression-free":[114],"survival":[115,192,259],"(PFS)":[116],"data":[117],"from":[118,130],"similarly":[120],"designed":[121],"trial,":[122,242],"this":[123,240],"closed":[125],"early.":[126],"Enrollment":[127],"(N=31)":[128],"August":[131],"2005-June":[132],"2008.":[133],"PATIENT":[134],"CHARACTERISTICS:":[135],"Median":[136,181],"age":[137],"55":[139],"years":[140],"(29-78);":[141],"58%":[142],"were":[143,146,152,179,260],"male;":[144],"71%":[145],"ECOG-PS":[147],"0.":[148],"Ten":[149],"cycles":[150],"(median)":[151],"completed":[153],"(range":[154],"2-62).":[155],"The":[156,262],"ORR":[157],"55%":[159],"(95%":[160,186,196],"confidence":[161],"interval":[162],"[CI],":[163],"36-73%);":[164],"11":[165],"patients":[166,177],"(35%)":[167],"had":[168,174],"stable":[169],"disease;":[170],"patient":[172],"(3%)":[173],"PD;":[175],"2":[176,211],"(6%)":[178],"unevaluable.":[180],"PFS":[182],"9":[184],"months":[185,195],"CI,":[187,197],"8.3-15.2":[188],"months);":[189],"median":[190],"overall":[191,258],"25.7":[194],"15.4-27.6":[198],"months).":[199],"Grade":[200],"3/4":[201],"toxicities":[202],"(>1":[203],"patient)":[204],"included":[205],"neutropenia":[206],"(25%),":[207],"rash":[208],"(23%;":[209],"grade":[210],"events,":[212],"45%),":[213],"diarrhea":[214],"(19%),":[215],"fatigue":[216],"(16%),":[217,219],"pain":[218],"anemia":[220],"(13%),":[221,224],"sensory":[222],"neuropathy":[223],"deep-vein":[225],"thrombosis":[226],"(10%),":[227,229],"nausea":[228],"pulmonary":[230],"embolism":[231],"(7%),":[232],"anorexia":[233],"(6%),":[234],"vomiting":[236],"(6%).":[237],"CONCLUSION:":[238],"In":[239],"limited":[241],"it":[243],"is":[244,285],"unclear":[245],"whether":[246],"contributed":[248],"FOLFOX/bevacizumab":[250],"efficacy,":[251],"although":[252],"rate,":[255],"PFS,":[256],"high.":[261],"regimen":[263],"generally":[265],"well-tolerated,":[266],"with":[267],"expected":[268],"skin":[269],"effects;":[270],"thromboembolic":[271],"rates":[272],"should":[273],"be":[274],"assessed":[275],"larger":[277],"analyses.":[278],"Cetuximab's":[279],"role":[280],"mCRC":[283],"likely":[286],"best":[287],"guided":[288],"by":[289],"K-RAS":[290],"testing":[291],"future":[293],"clinical":[294],"trials.":[295]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2015,"cited_by_count":3},{"year":2012,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}